van Trommel N E, Ngo Duc H, Massuger L F A G, Schijf C P T, Sweep C G J, Thomas C M G
Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Int J Gynecol Cancer. 2008 Mar-Apr;18(2):318-23. doi: 10.1111/j.1525-1438.2007.00993.x. Epub 2007 May 19.
The objective of the present study was to assess the diagnostic potential of serum human chorionic gonadotropin (hCG) ratios obtained at different intervals after evacuation of hydatidiform mole to diagnose persistent trophoblastic disease (PTD) and to compare its diagnostic accuracy with the current FIGO 2000 criteria as a gold standard. We calculated hCG ratios from serum hCG concentrations of 204 patients (86 with and 118 without PTD) registered with the Dutch Central Registry for Hydatidiform Moles between 1977-2004. The hCG ratios obtained in week 1, 3, and 5 after evacuation identified, respectively, 20%, 52%, and 79% of patients with PTD (median: 3.0 weeks) at the 95% specificity level, while FIGO 2000 criteria identified, respectively, 0%, 16%, and 66% (median: 4.7 weeks). It is concluded that a serum hCG ratio identifies patients with PTD approximately 2 weeks earlier than the internationally accepted FIGO 2000 criteria and identifies more than 75% of patients who develop PTD by the fifth week after evacuation.
本研究的目的是评估葡萄胎排空后不同时间间隔测得的血清人绒毛膜促性腺激素(hCG)比值对持续性滋养细胞疾病(PTD)的诊断潜力,并将其诊断准确性与当前作为金标准的国际妇产科联盟(FIGO)2000标准进行比较。我们根据1977年至2004年间在荷兰葡萄胎中央登记处登记的204例患者(86例患有PTD,118例未患PTD)的血清hCG浓度计算hCG比值。排空后第1周、第3周和第5周测得的hCG比值在95%特异性水平下分别识别出20%、52%和79%的PTD患者(中位数:3.0周),而FIGO 2000标准分别识别出0%、16%和66%(中位数:4.7周)。结论是,血清hCG比值识别PTD患者比国际公认的FIGO 2000标准早约2周,并且能识别出排空后第5周前发生PTD的75%以上的患者。